Strikingly, treatment with tocilizumab, a humanized monoclonal antibody that inhibits IL-6-STAT3 pathway through binding the IL-6 receptor (IL-6R), significantly reduced the viability and proliferation of TNBC cell lines with acute or chronic CIN, but had no effect on cells without CIN induction, or on untransformed breast epithelia cells. The gene discussed is IL6R; the disease is cervical squamous intraepithelial neoplasia.